Mixit

Composition
Mixit Tablet: Each film coated tablet contains Flupentixol Hydrochloride BP equivalent to 0.5 mg Flupentixol and Melitracen
Hydrochloride INN equivalent to 10 mg Melitracen.
Pharmacology
Mixit is the combined preparation of Flupentixol and Melitracen. Flupentixol is a thioxanthene neuroleptic with anxiolytic and
antidepressant properties of its own when given in small doses, and Melitracen is a tricyclic antidepressant (bipolar
thymoleptic with activating properties) in low doses. The neuroleptic effect of Flupentixol is achieved by mixed blockade of
post-synaptic dopamine D1 and D2 receptors in the brain and Melitracen relieved depression by inhibiting the reuptake of
serotonin and nor-epinephrine in the CNS. In combination the compounds render a preparation with antidepressant,
anxiolytic and activating properties.
Indication
Mixit (Flupentixol+Melitracen) is indicated in various types of anxiety and depression including-

• Psychogenic depression
• Depressive neuroses
• Masked depression
• Psychosomatic affections accompanied by anxiety and apathy
• Menopausal depressions
• Dysphoria and depression in alcoholics and drug-addicts

Dosage And Administration
Adults: Usually 2 tablets daily, morning and noon. In severe cases the morning dose may be increased to 2 tablets.
Elderly patient: 1 tablet in the morning.
Maintenance dose: Usually 1 tablet in the morning. In cases of insomnia or severe restlessness additional treatment with
sedative in the acute phase is recommended.
Contraindication
Mixit (Flupentixol+Melitracen) is contraindicated in i. known hypersensitivity to Flupentixol or Melitracen ii. MI, cardiac
conduction defects, arrhythmias (particularly heart block) iii. severe liver disease iv. narrow angle glaucoma v. CNS
depression states due to acute alcohol, barbiturate and opiate intoxications vi. Coma, phaeochromocytoma, porphyria vii.
state of excitement or overactivity, including mania viii. Who have received a MAOI within two weeks.
Precaution
Mixit (Flupentixol+Melitracen) should be used with caution in i. hepatic and renal impairment, cardiovascular disease,
hypotension, parkinson's disease, epilepsy, thyroid disease, myasthenia gravis, prostatic hypertrophy, severe respiratory
disease, history of jaundice, blood dyscrasias ii. history of urinary retention, concurrent electroconvulsive therapy iii. elderly,
who are particularly susceptible to postural hypotension and to hyper- or hypothermia in very hot or cold weather. Mixit
should be withdrawn gradually to reduce the risk of withdrawal symptoms. Mixit may cause drowsiness, dizziness or blurred
vision, so use caution during driving or operate machinery while taking Mixit.
Side Effect
In the recommended doses side effects are rare. These could be transient restlessness, drowsiness, dizziness, blurred
vision, insomnia, dry mouth, hypotension, tachycardia, constipation, blood disorders, menstrual disturbance, galactorrhoea,
gynaecomastia, sexual dysfunction, tremor and photosensitivity.
Use in Pregnancy and Lactation
Safety for use of Mixit (Flupentixol+Melitracen) during pregnancy and lactation has not been established. Use only when
clearly needed and when the potential benefits outweigh the potential hazards to the fetus/nursing infant.
Drug Interaction
Alcohol, barbiturates and other CNS depressants: Increase CNS depressive effect.
MAOI: May cause hypertensive crises.
Antihypertensives: Hypotensive effect is enhanced.
Antiarrhythmics: Increase risk of ventricular arrhythmias.
Sympathomimetics (Adrenaline and Nor-adrenaline): Increase risk of hypertension and arrhythmias.
Antihistamines: Possible increase antimuscarinic and sedative effects.
Analgesics: Sedative effect increased.
Antibacterials (Clarithromycin, Erythromycin, Moxifloxacin): Increase risk of ventricular arrhythmias.
Overdose
Symptoms: In case of overdosage the symptoms of intoxications by melitracen, especially of anticholinergic nature,
dominate. More rarely extrapyramidal symptoms due to flupentixol occur. Treatment: Symptomatic and supportive. Gastric
lavage should be carried out as soon as possible and activated charcoal may be administered. Measures aimed at
supporting the respiratory and cardiovascular systems should be instituted. Epinephrine (adrenaline) must not be used for
such patients. Convulsions may be treated with diazepam and extrapyramidal symptoms with biperiden.

Store in cool dry place and away from light. Keep out of the reach of children.